RxDoctor Payments Data

Libbie Lapp, PA

Medical · Kalispell, MTNPI 1225104052

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 122 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 38.1% of the total. Reporting peaked in 2023 at $802 and has fallen 93.1% since, to $55 in 2025.

$2,145in general payments, 2019–2025

Across 122 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$817
  • Lilly USA, LLC$304
  • Novartis$289
  • Amgen$149
  • Arcutis Biotherapeutics, Inc.$129
  • E.r. Squibb & Sons, L.L.C.$119
  • plus $338 from 7 others

What the payments were for

  • Food & beverage$2,145100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,145 in reported general payments places this provider in the 85th percentile of 134 medical providers in Montana.

See all medical providers in Montana

Medicare billing

Part B allowed, 2024
$117,065
Medicare patients
573
Services billed
3,213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast28$129,624
Clobetasol Propionate80$3,040
Metronidazole19$1,005
Ketoconazole73$924
Doxycycline Hyclate37$911
Clindamycin Phosphate30$581
Triamcinolone Acetonide86$532
MethotrexateMethotrexate Sodium13$342
ValacyclovirValacyclovir Hcl20$221
Prednisone19$160
Hydroxyzine Hcl12$71
Hydrocortisone18$59

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$149$129,62428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 134 medical providers in Montana.

Other medical in Kalispell

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →